Sequential switch from first-line anti-VEGF therapy to faricimab and subsequent aflibercept 8mg in treatment-resistant neovascular AMD
This retrospective study demonstrates that in patients with treatment-resistant neovascular AMD, sequentially switching from first-generation anti-VEGF therapy to faricimab and then to aflibercept 8mg yields progressive anatomical improvements and extended recurrence-free intervals while maintaining visual acuity and a comparable safety profile.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human eye relies on a delicate layer of tissue at the back of the retina to capture light and send images to the brain. In a condition called neovascular age-related macular degeneration, this area becomes damaged, prompting the growth of abnormal, leaky blood vessels. These vessels act like faulty pipes, leaking fluid that lifts and distorts the retina, causing rapid vision loss. For years, doctors have treated this by injecting medicine directly into the eye to stop the leakage. However, a significant number of patients do not respond well to the standard medicines; their eyes continue to leak fluid despite frequent injections, leaving them with persistent vision problems and a heavy burden of treatment.
Researchers at hospitals in France recently explored a new strategy for these stubborn cases. They focused on patients whose eyes had not dried up after receiving standard treatments. The team decided to try a two-step approach: first switching the patients to a newer drug called faricimab, and if that did not provide a lasting solution, switching them again to a higher dose of an older drug called aflibercept. The goal was to see if moving through these different treatments in sequence could finally stop the fluid and keep the eyes dry for longer periods without harming vision.
The study followed sixty eyes from forty-eight patients who had been struggling with persistent fluid despite regular injections of standard medicines. Every patient in the group had eyes that remained wet even when injections were given more frequently than every six weeks. The doctors first switched these patients to faricimab, a medicine designed to block two different pathways that cause blood vessel leakage. After treating the patients with this new drug, the researchers checked the results. They found that in forty-one of the sixty eyes, the fluid had completely disappeared. For the nineteen eyes that still showed some fluid after the first switch, the doctors then made the second change, moving the patients to the higher dose of aflibercept.
When the team examined the eyes after this second switch, the results showed a continued improvement. Forty-four of the sixty eyes were completely free of fluid. This included nine eyes that had remained wet even after the first switch to faricimab but finally dried up after moving to the higher dose of aflibercept. Conversely, a small number of eyes that had dried up with faricimab began to leak again after the switch to the higher dose, but the overall trend showed that the sequential strategy was effective at clearing fluid. The researchers noted that while the number of eyes that became completely dry was similar between the two drugs, the higher dose of aflibercept helped keep the eyes dry for slightly longer periods between injections. Specifically, the time without fluid recurrence averaged about five and a half weeks with the higher dose, compared to just under five weeks with the first drug.
Throughout this process, the patients' vision remained stable. The study measured how well the patients could see before and after each switch, and the results showed no significant change in visual acuity. The eyes did not get worse, nor did they show dramatic improvement in vision, but the crucial finding was that the vision was preserved while the physical swelling of the retina decreased. The thickness of the retina, which had been elevated by fluid, reduced more sharply when patients first switched to faricimab, but the higher dose of aflibercept also helped reduce this thickness effectively. Importantly, the doctors observed no new cases of scarring, tissue loss, or inflammation in the eyes during the study, suggesting that this two-step approach was safe for the patients.
The researchers concluded that for patients with treatment-resistant macular degeneration, moving from one drug to another in a specific order can be a viable path forward. By starting with faricimab and then transitioning to a higher dose of aflibercept, doctors were able to clear fluid from the eyes of many patients who had previously failed other treatments. While the study did not prove that one drug is superior to the other in every case, it demonstrated that using them sequentially offers a way to manage difficult cases, maintaining vision and extending the time between necessary injections. This approach provides a flexible option for clinicians dealing with eyes that refuse to respond to standard care, offering hope for better long-term stability in a condition that has long been difficult to control.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.